Compare Stocks: VTYX, TLX, LEGN, and VCYT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$19.27 +2.0%	$19.54	$16.24 ▼ $37.50	$3.66B	0.57	2.00 million shs	979,565 shs
TLX Telix Pharmaceuticals	$9.15 -4.1%	$11.34	$6.28 ▼ $13.11	$3.25B	-0.17	403,954 shs	413,440 shs
VCYT Veracyte	$47.93 +4.1%	$43.59	$29.45 ▼ $60.91	$3.70B	1.95	1.26 million shs	906,002 shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	+1.96%	+4.27%	+4.44%	-13.28%	-39.99%
TLX Telix Pharmaceuticals	-4.09%	-14.41%	-18.81%	-10.47%	-15.12%
VCYT Veracyte	+4.11%	+11.15%	+9.38%	-15.33%	+37.93%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+262.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$19.27 +2.0%	$19.54	$16.24 ▼ $37.50	$3.66B	0.57	2.00 million shs	979,565 shs
TLX Telix Pharmaceuticals	$9.15 -4.1%	$11.34	$6.28 ▼ $13.11	$3.25B	-0.17	403,954 shs	413,440 shs
VCYT Veracyte	$47.93 +4.1%	$43.59	$29.45 ▼ $60.91	$3.70B	1.95	1.26 million shs	906,002 shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	+1.96%	+4.27%	+4.44%	-13.28%	-39.99%
TLX Telix Pharmaceuticals	-4.09%	-14.41%	-18.81%	-10.47%	-15.12%
VCYT Veracyte	+4.11%	+11.15%	+9.38%	-15.33%	+37.93%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+262.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	2.53	Moderate Buy	$54.69	183.82% Upside
TLX Telix Pharmaceuticals	2.80	Moderate Buy	$20.50	124.04% Upside
VCYT Veracyte	2.64	Moderate Buy	$55.78	16.37% Upside
VTYX Ventyx Biosciences	2.00	Hold	$14.00	N/A

Current Analyst Ratings Breakdown

Latest VTYX, TLX, LEGN, and VCYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$22.00
10/19/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/13/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$74.00 ➝ $68.00
10/9/2026	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$35.00 ➝ $33.00
10/8/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$58.00 ➝ $56.00
10/2/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/28/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$65.00
9/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$65.00
9/25/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00
9/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C+) ➝ Hold (C)

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$1.03B	3.63	N/A	N/A	$5.43 per share	3.55
TLX Telix Pharmaceuticals	$803.79M	3.87	$0.04 per share	226.26	$1.23 per share	7.44
VCYT Veracyte	$561.90M	6.86	$1.55 per share	30.91	$16.57 per share	2.89
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	16.61	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	32.68	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	$66.35M	$1.41	33.99	31.95	N/A	20.37%	9.26%	8.61%	11/4/2026 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.50	N/A	N/A	N/A	N/A	-48.11%	-43.89%	N/A

Latest VTYX, TLX, LEGN, and VCYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	LEGN Legend Biotech	$0.01	N/A	N/A	N/A	$361.46 million	N/A
11/4/2026	Q3 2026	VCYT Veracyte	$0.4103	N/A	N/A	N/A	$147.16 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	N/A	3.04	2.94
TLX Telix Pharmaceuticals	1.16	2.01	1.85
VCYT Veracyte	N/A	9.16	8.80
VTYX Ventyx Biosciences	N/A	17.86	17.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
TLX Telix Pharmaceuticals	N/A
VCYT Veracyte	N/A
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
TLX Telix Pharmaceuticals	N/A
VCYT Veracyte	1.60%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
TLX Telix Pharmaceuticals	1,184	340.33 million	N/A	N/A
VCYT Veracyte	755	80.39 million	79.11 million	Optionable
VTYX Ventyx Biosciences	30	71.76 million	61.36 million	Optionable

VTYX, TLX, LEGN, and VCYT Headlines

Recent News About These Companies

Ventyx Biosciences Shareholders Approve Merger With Eli Lilly

June 12, 2026 | theglobeandmail.com

Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

April 29, 2026 | globenewswire.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

February 5, 2026 | businesswire.com

Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple

January 26, 2026 | finance.yahoo.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 23, 2026 | prnewswire.com

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, PEN, CWAN Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026 | caledonianrecord.comC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 15, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 13, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, ONTF, FFIC, OCFC Shareholders to Contact the Firm to Discuss ...

January 13, 2026 | caledonianrecord.comC

LifeSci Capital Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

January 12, 2026 | theglobeandmail.com

UBS downgrades Ventyx Biosciences (VTYX)

January 10, 2026 | msn.com

Oppenheimer downgrades Ventyx Biosciences (VTYX)

January 9, 2026 | msn.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

January 8, 2026 | prnewswire.com

Lilly confirms bid to acquire Ventyx Biosciences

January 8, 2026 | thepharmaletter.comT

Canaccord Genuity downgrades Ventyx Biosciences (VTYX)

January 8, 2026 | msn.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

January 8, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

January 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, LEGN, and VCYT Company Descriptions

Legend Biotech NASDAQ:LEGN

$19.27 +0.37 (+1.96%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$19.06 -0.21 (-1.07%)

As of 10/23/2026 07:37 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Telix Pharmaceuticals NASDAQ:TLX

$9.15 -0.39 (-4.09%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$9.23 +0.08 (+0.84%)

As of 10/23/2026 07:30 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Veracyte NASDAQ:VCYT

$47.93 +1.89 (+4.11%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$48.02 +0.09 (+0.19%)

As of 10/23/2026 07:31 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TLX, LEGN, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TLX, LEGN, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TLX, LEGN, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, LEGN, and VCYT Company Descriptions

Legend Biotech NASDAQ:LEGN

Telix Pharmaceuticals NASDAQ:TLX

Veracyte NASDAQ:VCYT

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TLX, LEGN, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TLX, LEGN, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TLX, LEGN, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, LEGN, and VCYT Company Descriptions

Legend Biotech NASDAQ:LEGN

Telix Pharmaceuticals NASDAQ:TLX

Veracyte NASDAQ:VCYT

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools